{"ticker": {"uuid": "33cbadba-33fd-4bf7-b40f-c72f6f476f3e", "symbol": "ALEC", "name": "Alector Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Alector (ALEC) Proxy filing Summary", "summary": "Alector (ALEC) has announced its annual meeting for June 17, 2026, to be held virtually. Key proposals include the election of three directors, the ratification of Ernst & Young, LLP as the independent accounting firm, and an advisory vote on executive compensation, all recommend", "url": "https://quartr.com/events/alector-inc-alec-proxy-filing_3Pzqal4A", "source_name": "Quartr", "published_at": "2026-07-14T01:10:10", "published_display": "14 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Goldman Sachs 45th Annual Global Healthcare Conference Summary", "summary": "This article summarizes Alector's presentation at the Goldman Sachs 45th Annual Global Healthcare Conference, highlighting its strategic focus on eradicating neurodegenerative diseases by leveraging human genetics, immunology, and neuroscience. The company's clinical pipeline inc", "url": "https://quartr.com/events/alector-alec-goldman-sachs-45th-annual-global-healthcare-conference_3PzqcUEe", "source_name": "Quartr", "published_at": "2026-07-14T00:00:00", "published_display": "14 Jul 2026 00:00", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership", "summary": "GSK's licensor Hansoh Pharmaceutical announced positive Phase 3 data for risvutatug rezetecan (Ris-Rez) in advanced or relapsed small-cell lung cancer, demonstrating improved overall survival. This marks the first positive Phase 3 survival data for a B7-H3-targeted antibody-drug ", "url": "https://www.sahmcapital.com/news/content/gsk-adds-positive-phase-3-lung-cancer-data-ends-alector-partnership-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-12T20:00:00", "published_display": "12 Jul 2026 20:00", "sentiment": "negative", "sentiment_pct": 13, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Alector Inc For: 9 July By Investing.com", "summary": "This article announces the filing of a Form 4 by Alector Inc. on July 9th, as reported by Investing.com. It is a brief news item indicating insider transaction activity for the company Alector (ALEC). The article also lists various market data like indices, commodities, and stock", "url": "https://ng.investing.com/news/stock-market-news/form-4-alector-inc-for-9-july-93CH-2593782", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T11:39:38", "published_display": "10 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector and GSK partnership to end after dementia, Alzheimer's drug failures", "summary": "Alector announced GSK is terminating their neuroscience collaboration agreement after two experimental antibody drugs for frontotemporal dementia and Alzheimer's disease failed in clinical trials. This decision follows setbacks for latozinemab in a late-stage study and nivisnebar", "url": "https://finance.yahoo.com/healthcare/articles/alector-gsk-partnership-end-dementia-212018192.html", "source_name": "Market source", "published_at": "2026-07-09T21:51:31", "published_display": "09 Jul 2026 21:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) awards 20,000 RSUs to principal accounting officer", "summary": "Alector, Inc. (ALEC) has awarded 20,000 Restricted Stock Units (RSUs) to its Principal Accounting Officer, Grace Wong-Sarad. These RSUs will vest in 12 equal quarterly installments starting September 1, 2026, and after this grant, Wong-Sarad holds 115,461 shares of common stock. ", "url": "https://www.stocktitan.net/sec-filings/ALEC/form-4-alector-inc-insider-trading-activity-b8c756e1a67a.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:51:30", "published_display": "09 Jul 2026 19:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK Walks Away From Alector - Pipeline Reset Story Begins (NASDAQ:ALEC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPWEVJb01FN3BzQnJ3UjZod2hpN1VpcjRsRllRMW92M2RjNGhaSVpLZExhWkRiMG4tNHNaelB3OGY0NEtHVG9najNRQUhLaHpOek1ZTGtVSW43SWpoYU5zenpRYzQ5RmFYWGhlNU5KcElaQmdHLWk1LWhxTFF0djZKTFIxeXJZYU45U1JyYV9jaUl0eXM1aFBoTW5aaU0?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-09T14:05:49+00:00", "published_display": "09 Jul 2026 14:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK ends Alector alliance as both lead assets fail", "summary": "GSK has terminated its five-year neuroscience collaboration with Alector after two experimental antibody drugs, latozinemab and nivisnebart, failed in clinical trials for frontotemporal dementia and Alzheimer's disease, respectively. While GSK exits the partnership, it continues ", "url": "https://www.emjreviews.com/emj-gold/news/gsk-ends-alector-alliance-as-both-lead-assets-fail/", "source_name": "European Medical Journal", "published_at": "2026-07-09T12:51:31", "published_display": "09 Jul 2026 12:51", "sentiment": "negative", "sentiment_pct": 9, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK ends brain drug alliance with Alector", "summary": "", "url": "https://finance.yahoo.com/m/2339c412-da84-33f9-8b41-eae09428e37c/gsk-ends-brain-drug-alliance.html", "source_name": "BioPharma Dive", "published_at": "2026-07-09T11:45:00+00:00", "published_display": "09 Jul 2026 11:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector stock plummets 13% as GSK terminates neuroscience pact", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQbUhuc01BZGE4ZW9QT19XSHB2MkVrS0pCZkU1eHh4dmNHcU9WTzZHcmg4cUFSVE1xVzdzMzVZYzBrMFVmT3JNZ3JSdGZVOVk1ZWR6cWFUbm5VcllUOXgwN2RPSVRxNk1jQkgzRzNrWENlVHA1VFhuanNTa1loWTkxbzQ5X3JPTmh0SkRXc2pYc2M0YXNFQS1LVjVMX1cySlY3c0dlbktfQUlLQkNqdjdxeXN3?oc=5", "source_name": "MSN", "published_at": "2026-07-09T05:44:52+00:00", "published_display": "09 Jul 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Shares Drop 13% Following Termination of GSK Collaboration", "summary": "Alector Inc. (ALEC) shares dropped 13% after GSK terminated their collaboration on two experimental antibody drugs due to clinical trial failures, including latozinemab for frontotemporal dementia and nivisnebart for Alzheimer's. This setback highlights significant challenges for", "url": "https://www.gurufocus.com/news/8950863/alector-alec-shares-drop-13-following-termination-of-gsk-collaboration", "source_name": "GuruFocus", "published_at": "2026-07-09T06:39:15", "published_display": "09 Jul 2026 06:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector stock plummets 13% as GSK terminates neuroscience pact (GSK:NYSE)", "summary": "Alector's stock plunged 13% after GSK terminated their neuroscience collaboration due to clinical setbacks with two experimental antibody drugs. GSK's shares eased by 1.5% following the announcement. This decision highlights the risks associated with pharmaceutical drug developme", "url": "https://seekingalpha.com/news/4612468-alector-stock-plummets-13-as-gsk-terminates-neuroscience-pact", "source_name": "Seeking Alpha", "published_at": "2026-07-09T04:39:15", "published_display": "09 Jul 2026 04:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) sees GSK end antibody collaboration while repaying $10.4M loan", "summary": "Alector (ALEC) announced that GSK has terminated their 2021 collaboration and license agreement for progranulin-elevating antibodies latozinemab and nivisnebart, effective January 2, 2027. This decision follows the discontinuation of Phase 3 and Phase 2 trials for these programs ", "url": "https://www.stocktitan.net/sec-filings/ALEC/8-k-alector-inc-reports-material-event-df5d087be3ab.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:28", "published_display": "08 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector to End GSK Progranulin Collaboration; Repays $10.4 Million Hercules Loan", "summary": "Alector announced the termination of its collaboration and license agreement with GSK for progranulin-elevating antibodies, effective January 2, 2027, following clinical trial setbacks. Concurrently, Alector repaid a $10.4 million loan to Hercules Capital, including principal, in", "url": "https://www.tradingview.com/news/tradingview:64b3b3d0b5206:0-alector-to-end-gsk-progranulin-collaboration-repays-10-4-million-hercules-loan/", "source_name": "TradingView", "published_at": "2026-07-08T20:10:28", "published_display": "08 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "0Z2 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Alector, Inc. (0Z2) stock, based on analyst opinions. It includes financial data such as past earnings, revenue, net income, and EBITDA, along with important dates like the next earnings report. The piece also answers frequent", "url": "https://www.tradingview.com/symbols/HAM-0Z2/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:39", "published_display": "26 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector, Inc. Actuals & Estimates (NASDAQ:ALEC)", "summary": "This article provides an overview of Alector, Inc. (NASDAQ:ALEC) stock performance, financial estimates, and analyst forecasts. It covers metrics such as current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates. The informatio", "url": "https://www.tradingview.com/symbols/NASDAQ-ALEC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:09:39", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALEC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast, price target, and prediction for Alector, Inc. (ALEC) stock for 2027, based on analyst opinions and financial data. It covers current stock price, historical performance, earnings reports, market capitalization, and volatility, along with a discl", "url": "https://www.tradingview.com/symbols/NASDAQ-ALEC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:40:50", "published_display": "26 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Alector, Inc. \u2013 NASDAQ:ALEC", "summary": "The article displays the enterprise value to EBIT forward for Alector, Inc. (NASDAQ: ALEC). It appears to be a financial data snippet from a larger platform, possibly TradingView, focusing solely on this specific financial metric for the given company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALEC/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:11:01", "published_display": "25 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Alector, Inc. \u2013 NASDAQ:ALEC", "summary": "This article briefly highlights the \"Enterprise value to revenue forward\" metric for Alector, Inc. (NASDAQ: ALEC). It appears to be a financial data point provided by TradingView, a financial markets platform. The content primarily focuses on the company's financial data and gene", "url": "https://www.tradingview.com/symbols/NASDAQ-ALEC/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:53", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Alector, Inc. \u2013 GETTEX:0Z2", "summary": "The article discusses the \"Price to book forward\" metric for Alector, Inc. (GETTEX:0Z2), available on TradingView under its financial data section. It highlights that this specific financial data point is \"Made by humans\" and is part of the comprehensive information available for", "url": "https://www.tradingview.com/symbols/GETTEX-0Z2/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T10:11:45", "published_display": "25 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (NASDAQ: ALEC) director receives new RSU and stock option awards", "summary": "Alector (NASDAQ: ALEC) director Elizabeth A. Garofalo was granted new equity compensation on June 17, 2026. This included 28,700 restricted stock units (RSUs) vesting on June 17, 2027, or the date of the next annual stockholder meeting, and stock options for 9,450 shares vesting ", "url": "https://www.stocktitan.net/sec-filings/ALEC/form-4-alector-inc-insider-trading-activity-cec12f2be4ed.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:39:18", "published_display": "22 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Alector Inc (ALEC) currently has a weak financial status and low operating efficiency, ranking 312 out of 389 in the Biotechnology & Medical Research industry with a financial score of 5.88. The company reported a significant year-over-year decrease in revenue (71.53%) and net pr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/financial-health", "source_name": "TradingKey", "published_at": "2026-06-22T17:09:17", "published_display": "22 Jun 2026 17:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Institutional Confidence", "summary": "Alector Inc (ALEC) has an institutional shareholding score of 7.00, placing it 81st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 80.95%, showing a 17.91% decrease quarter-over-quarter. James Simons is the largest institutional sha", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T03:09:27", "published_display": "19 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Stock Faces Mixed Analyst Target Changes On Tau Therapy Readthrough", "summary": "Alector's fair value remains steady at US$3.10 per share, despite mixed analyst sentiment regarding tau-targeting therapies in Alzheimer's. While some analysts view Biogen's CELIA data as validating the approach and Alector's potential, others caution that the CELIA trial missed ", "url": "https://sg.finance.yahoo.com/news/alector-alec-stock-faces-mixed-001825375.html", "source_name": "Market source", "published_at": "2026-06-19T00:18:00", "published_display": "19 Jun 2026 00:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Alector Inc (ALEC), noting its current valuation score of 6.91 in the Biotechnology & Medical Research industry. It details the stock's current price, market cap, and P/E ratio, while indicating that P/B, P/S, and P/CF data have not y", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:52", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Alector Inc (ALEC), including its current price momentum score, support and resistance levels. It details various technical indicators like MACD, RSI, and moving averages, offering buy, sell, or neutral signals. The analysis suggests ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/technical", "source_name": "TradingKey", "published_at": "2026-06-18T07:39:52", "published_display": "18 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Alector Inc (ALEC), listing major shareholders and providing a breakdown of shareholder types, including investment advisors, hedge funds, and venture capital. It also presents institutional shareholding data over several quarters", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T05:38:57", "published_display": "18 Jun 2026 05:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article concerns Alector Inc (ALEC) and its revenue breakdown by business segments, regional revenue, and profit contribution. However, the article states that relevant data for these categories have not been disclosed by the company yet. It primarily serves as a placeholder", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T03:38:57", "published_display": "18 Jun 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) director receives 28,700 RSUs and 9,450-share option grant", "summary": "Alector, Inc. director Richard H. Scheller received 28,700 restricted stock units (RSUs) and a stock option for 9,450 shares of common stock, as detailed in a recent Form 4 SEC filing. The RSUs vest on the earlier of June 17, 2027, or the company's next annual stockholder meeting", "url": "https://www.stocktitan.net/sec-filings/ALEC/form-4-alector-inc-insider-trading-activity-d45744dd978d.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:39:52", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (NASDAQ: ALEC) director receives RSU and stock option grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOUlZ0RHBDWFlleEN2V2l5N290ZjhfS24wMGJ3d3RMLWlnakxxaHNPVDJIVWZnTlpFRXR5OXUtUUgtSWZNWUJ2TmdhdS1oUDNrd1JpbDFQNjZ3b3hmWjF1TGhta2pOaE5yRGxncDJQbkpvNHNLc0RweVVMcDBjMjE0Y2R0bWhaRURHZHFlSDkzRU9EUVFfZHNTdVBHTzVIVTBlMl9wTWh3QUY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity grants lift Alector (ALEC) director Errol DeSouza\u2019s holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWG15akVkQnRYYTQ4NGg2eVQ4UC11WWN2dmVaWjhxSWw2Z2RwS21jM3NkNm8wRlROd3JyWEg0V1d1eWhtQl9DZ3hielhnNHQ1WURJZEtiLWVYQzhJVHhVclNPTDJGUVhNYUxzZzBwY2RuajR6RjZEYkVXeFRnYmF6VTJodHdtT1YxRFpmc0lLWTJMdkJGVDhCMVNMdXYxazlram1mcWRIN1Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) director awarded stock and options vesting through 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYmJsdzdsQkhIeHRLWDMxR2hPeWlxcEdBMjhQekxhdXpGQmQxZjN5UzZzZFNtNXNyMUVwTVJJblZKa1BUbERfbHd0d1B4UXplXzlOWngtQzRaVC04TVIzNTg5ajg2cE9FRHhjcDFFMlR3VG9GLWNqSFdsalBiSGdzQVJkbFRudnNzTDlzQjlmV05OeTJyRGdjTzNieEdRUmVTNnZweUV0MjA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Insider Has Just Sold Shares In Alector", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHJtLTJGblZUdFZBSDNrWXNEUXVFZm5WZ1JwRkoyVGVPOGJISU5NUHppZHJ4S2FGRnJ0a3VZcC1CeG13TGVKSzNzUnlOVnMxOXVSb1pQaVJfa2xkSlVCNUs4NHFhc1hLYUFCLW5hZDNhaVpSekNiSUpXcWhHT3I2Uy1DcDBIZHdFZTF0R2tYVC1Gclo5RHAtN1dwZWhvX3BNejBPNGNn?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alector-alec-reports-q1-loss-230508350.html", "source_name": "Zacks", "published_at": "2026-05-07T23:05:08+00:00", "published_display": "07 May 2026 23:05", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/alector-q1-earnings-snapshot-210514149.html", "source_name": "Associated Press", "published_at": "2026-05-07T21:05:14+00:00", "published_display": "07 May 2026 21:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alector-reports-first-quarter-2026-200500095.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T20:05:00+00:00", "published_display": "07 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOaGpUcURHTV9lbTFiY0NMZTJrSC1yQnNpbmt6eld3Q1dJSUUzaDB3YTVMbFJaelduSm5EUHpQa19WX2NQMlN4Z2hQYWp3dTVGeEwtXzJET3BJWm1DN0dBUUR2R2VtdV95UE9OOEt1bDRPaHBUVTBqUzdhYXQwSkpjVUM2SlA4bUdacmN6aUNWS19uUl9UYkZqOFpCWGU?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley raises Alector stock price target on pipeline focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQa3M0NlExSGlHbTlRdFRDWmQxLVc0QVlBVEYwakZWLTRVU3liTnRyZWpzbWNZOEZMRmFKMHZ4RkpwdHYxbkJCaldLNk5McVRqZjBXVUhld2oxTENHcjZEQUtjWVBsaDNGT3JpdFhoWnhQLWNZVTFGd1VQWVNQNVhici1wSWZsNjRPZTFNN3NpYUJaRXctT2c1M0Jpa2tCV3NTRWZQYTdybTVQWXAwbTFLRkJLaHQ4dWJSOGl6OWI5Q2YtTlda?oc=5", "source_name": "Investing.com", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector drops GSK-partnered Alzheimer\u2019s drug (ALEC:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPSjd0TXVrUzQ2Zmx6RXJ0dGI2bXNLSG12bVp5dmZ5bDBYa3Y5MWFpdGhTNlZzYmpNd1RGRUlDRV9Fc0htdVdkLXh0WFcyMDhlcmVCZTRnT0FRLVdQSDlUc2w3TzBvX0NWTjhnRlJ0X2Uxc3VTUmZ3N083b1QycnlSV1hLNTNJd0FY?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNdmt3NGxGdjBsa0IyYkoyaFpGUnRMay12cWMxcHR5cDZZMzFxbzNNcENwTGlQeHBhY1ZfZF9nSXRuMUJXdUJlYW1Hci1hM0JYcnNHcTZPN1JBcVBDeTN6T19UR3IxRnEwcUVTbUpWT1NkN3I1bURYZGQxbFFURGNkc0R2dlFaY29VQjdsbUVDdjc2TV9VekJpd19taWhyakZLbVN0eG1DNlVtak0?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alector stock upgraded at Cantor Fitzgerald (ALEC:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPQnlwYjRFOFB5S24zamZ0Zkw5VmN6ZTlUY1FkOGEtWVBMN0dWc2Z2Rk5TMjJtNUR1ZnpTcURWb1c3ZXlkV2JLUDB1cFdqT1d3MklKODhybXd5RlNBMmhRaDdOX01QVzBpTjlrQndQZFJUM3pTcEdjeFMxR0FJMTBtY0tpekc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alector Stock Jumps On Upgrade, But AL101 Interim Data Will Be Key (NASDAQ:ALEC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQdU9XR0Izdk1pRk5hR2p2cEdvRVl2UFZZWmJIVElsUzBrVTQyMjNOTjdGWGIzNlVkX0tWSjA5REViUjNHaVlDeGN1T2FBVm5CY0tlaTJyNTNGYmN1NDZyTkt1NDdURW5mWlNhZWE1ajN0Mzg3RGxNQjhmdkR1NmtmX0lMSGlvUmpJQkhaMkttaTNhZWpxUVJrOGt6S3UwNkQzM1F1by1RcFF6Zw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-22T08:00:00+00:00", "published_display": "22 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst (ALEC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQNU5jTjlMdEdmaVI3X29vNmVsNElSamR3TmpzdnZONUJZTmZjVEk0a0ZkaFVxSktSTHUyRnFfaHRheG5xZm5uRUlXWU1NQkdlalNldkZsTGNhSmVJazkwOTZnaXlWV3dlUlhhS2R1elhhTVpxcW5kb09tSmdrZ1hmUUh6RTRaR29jTnRFT1laSm1xUWxuSzZuMWxDMUhENlVqUHpadmMzSm52T2g1QWQ4?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Is Down 54.3% After Latozinemab Phase 3 Failure and Major Restructuring \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-24T07:00:00+00:00", "published_display": "24 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Stock Forecast and Price Target 2026 $ALEC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9OT2FUWXB3T09DWllleWRLbk1DbGtiVmk3VjMtSXRlSDdxVHkxOWQxMzhObjE5TmxUSzVBb1hBRk5kdEJVdHRxVkJFS2plNmlSc1pfc2ROdzVIU1pxVlVvWTJRRVgtZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:36:45+00:00", "published_display": "11 May 2024 13:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Stock Price, News & Analysis $ALEC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE4wTXZaeWVyMzFoeVJmd3FfNlBEc3NUMHBQMnByS1JBRldxV01pcnVwNE9NU3VNb1dRRDdQZmIyTEh1NmlZVlloaVpWeWx5ZnhGQVdyaV9pQVZOQQ?oc=5", "source_name": "MarketBeat", "published_at": "2019-02-12T01:18:12+00:00", "published_display": "12 Feb 2019 01:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Alector (ALEC) Proxy filing Summary", "summary": "Alector (ALEC) has announced its annual meeting for June 17, 2026, to be held virtually. Key proposals include the election of three directors, the ratification of Ernst & Young, LLP as the independent accounting firm, and an advisory vote on executive compensation, all recommend", "url": "https://quartr.com/events/alector-inc-alec-proxy-filing_3Pzqal4A", "source_name": "Quartr", "published_at": "2026-07-14T01:10:10", "published_display": "14 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Goldman Sachs 45th Annual Global Healthcare Conference Summary", "summary": "This article summarizes Alector's presentation at the Goldman Sachs 45th Annual Global Healthcare Conference, highlighting its strategic focus on eradicating neurodegenerative diseases by leveraging human genetics, immunology, and neuroscience. The company's clinical pipeline inc", "url": "https://quartr.com/events/alector-alec-goldman-sachs-45th-annual-global-healthcare-conference_3PzqcUEe", "source_name": "Quartr", "published_at": "2026-07-14T00:00:00", "published_display": "14 Jul 2026 00:00", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership", "summary": "GSK's licensor Hansoh Pharmaceutical announced positive Phase 3 data for risvutatug rezetecan (Ris-Rez) in advanced or relapsed small-cell lung cancer, demonstrating improved overall survival. This marks the first positive Phase 3 survival data for a B7-H3-targeted antibody-drug ", "url": "https://www.sahmcapital.com/news/content/gsk-adds-positive-phase-3-lung-cancer-data-ends-alector-partnership-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-12T20:00:00", "published_display": "12 Jul 2026 20:00", "sentiment": "negative", "sentiment_pct": 13, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Alector Inc For: 9 July By Investing.com", "summary": "This article announces the filing of a Form 4 by Alector Inc. on July 9th, as reported by Investing.com. It is a brief news item indicating insider transaction activity for the company Alector (ALEC). The article also lists various market data like indices, commodities, and stock", "url": "https://ng.investing.com/news/stock-market-news/form-4-alector-inc-for-9-july-93CH-2593782", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T11:39:38", "published_display": "10 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector and GSK partnership to end after dementia, Alzheimer's drug failures", "summary": "Alector announced GSK is terminating their neuroscience collaboration agreement after two experimental antibody drugs for frontotemporal dementia and Alzheimer's disease failed in clinical trials. This decision follows setbacks for latozinemab in a late-stage study and nivisnebar", "url": "https://finance.yahoo.com/healthcare/articles/alector-gsk-partnership-end-dementia-212018192.html", "source_name": "Market source", "published_at": "2026-07-09T21:51:31", "published_display": "09 Jul 2026 21:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) awards 20,000 RSUs to principal accounting officer", "summary": "Alector, Inc. (ALEC) has awarded 20,000 Restricted Stock Units (RSUs) to its Principal Accounting Officer, Grace Wong-Sarad. These RSUs will vest in 12 equal quarterly installments starting September 1, 2026, and after this grant, Wong-Sarad holds 115,461 shares of common stock. ", "url": "https://www.stocktitan.net/sec-filings/ALEC/form-4-alector-inc-insider-trading-activity-b8c756e1a67a.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:51:30", "published_display": "09 Jul 2026 19:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK Walks Away From Alector - Pipeline Reset Story Begins (NASDAQ:ALEC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPWEVJb01FN3BzQnJ3UjZod2hpN1VpcjRsRllRMW92M2RjNGhaSVpLZExhWkRiMG4tNHNaelB3OGY0NEtHVG9najNRQUhLaHpOek1ZTGtVSW43SWpoYU5zenpRYzQ5RmFYWGhlNU5KcElaQmdHLWk1LWhxTFF0djZKTFIxeXJZYU45U1JyYV9jaUl0eXM1aFBoTW5aaU0?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-09T14:05:49+00:00", "published_display": "09 Jul 2026 14:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK ends Alector alliance as both lead assets fail", "summary": "GSK has terminated its five-year neuroscience collaboration with Alector after two experimental antibody drugs, latozinemab and nivisnebart, failed in clinical trials for frontotemporal dementia and Alzheimer's disease, respectively. While GSK exits the partnership, it continues ", "url": "https://www.emjreviews.com/emj-gold/news/gsk-ends-alector-alliance-as-both-lead-assets-fail/", "source_name": "European Medical Journal", "published_at": "2026-07-09T12:51:31", "published_display": "09 Jul 2026 12:51", "sentiment": "negative", "sentiment_pct": 9, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK ends brain drug alliance with Alector", "summary": "", "url": "https://finance.yahoo.com/m/2339c412-da84-33f9-8b41-eae09428e37c/gsk-ends-brain-drug-alliance.html", "source_name": "BioPharma Dive", "published_at": "2026-07-09T11:45:00+00:00", "published_display": "09 Jul 2026 11:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector stock plummets 13% as GSK terminates neuroscience pact", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQbUhuc01BZGE4ZW9QT19XSHB2MkVrS0pCZkU1eHh4dmNHcU9WTzZHcmg4cUFSVE1xVzdzMzVZYzBrMFVmT3JNZ3JSdGZVOVk1ZWR6cWFUbm5VcllUOXgwN2RPSVRxNk1jQkgzRzNrWENlVHA1VFhuanNTa1loWTkxbzQ5X3JPTmh0SkRXc2pYc2M0YXNFQS1LVjVMX1cySlY3c0dlbktfQUlLQkNqdjdxeXN3?oc=5", "source_name": "MSN", "published_at": "2026-07-09T05:44:52+00:00", "published_display": "09 Jul 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Shares Drop 13% Following Termination of GSK Collaboration", "summary": "Alector Inc. (ALEC) shares dropped 13% after GSK terminated their collaboration on two experimental antibody drugs due to clinical trial failures, including latozinemab for frontotemporal dementia and nivisnebart for Alzheimer's. This setback highlights significant challenges for", "url": "https://www.gurufocus.com/news/8950863/alector-alec-shares-drop-13-following-termination-of-gsk-collaboration", "source_name": "GuruFocus", "published_at": "2026-07-09T06:39:15", "published_display": "09 Jul 2026 06:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector stock plummets 13% as GSK terminates neuroscience pact (GSK:NYSE)", "summary": "Alector's stock plunged 13% after GSK terminated their neuroscience collaboration due to clinical setbacks with two experimental antibody drugs. GSK's shares eased by 1.5% following the announcement. This decision highlights the risks associated with pharmaceutical drug developme", "url": "https://seekingalpha.com/news/4612468-alector-stock-plummets-13-as-gsk-terminates-neuroscience-pact", "source_name": "Seeking Alpha", "published_at": "2026-07-09T04:39:15", "published_display": "09 Jul 2026 04:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) sees GSK end antibody collaboration while repaying $10.4M loan", "summary": "Alector (ALEC) announced that GSK has terminated their 2021 collaboration and license agreement for progranulin-elevating antibodies latozinemab and nivisnebart, effective January 2, 2027. This decision follows the discontinuation of Phase 3 and Phase 2 trials for these programs ", "url": "https://www.stocktitan.net/sec-filings/ALEC/8-k-alector-inc-reports-material-event-df5d087be3ab.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:28", "published_display": "08 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector to End GSK Progranulin Collaboration; Repays $10.4 Million Hercules Loan", "summary": "Alector announced the termination of its collaboration and license agreement with GSK for progranulin-elevating antibodies, effective January 2, 2027, following clinical trial setbacks. Concurrently, Alector repaid a $10.4 million loan to Hercules Capital, including principal, in", "url": "https://www.tradingview.com/news/tradingview:64b3b3d0b5206:0-alector-to-end-gsk-progranulin-collaboration-repays-10-4-million-hercules-loan/", "source_name": "TradingView", "published_at": "2026-07-08T20:10:28", "published_display": "08 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "0Z2 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Alector, Inc. (0Z2) stock, based on analyst opinions. It includes financial data such as past earnings, revenue, net income, and EBITDA, along with important dates like the next earnings report. The piece also answers frequent", "url": "https://www.tradingview.com/symbols/HAM-0Z2/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:39", "published_display": "26 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector, Inc. Actuals & Estimates (NASDAQ:ALEC)", "summary": "This article provides an overview of Alector, Inc. (NASDAQ:ALEC) stock performance, financial estimates, and analyst forecasts. It covers metrics such as current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates. The informatio", "url": "https://www.tradingview.com/symbols/NASDAQ-ALEC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:09:39", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALEC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast, price target, and prediction for Alector, Inc. (ALEC) stock for 2027, based on analyst opinions and financial data. It covers current stock price, historical performance, earnings reports, market capitalization, and volatility, along with a discl", "url": "https://www.tradingview.com/symbols/NASDAQ-ALEC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:40:50", "published_display": "26 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Alector, Inc. \u2013 NASDAQ:ALEC", "summary": "The article displays the enterprise value to EBIT forward for Alector, Inc. (NASDAQ: ALEC). It appears to be a financial data snippet from a larger platform, possibly TradingView, focusing solely on this specific financial metric for the given company.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALEC/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:11:01", "published_display": "25 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Alector, Inc. \u2013 NASDAQ:ALEC", "summary": "This article briefly highlights the \"Enterprise value to revenue forward\" metric for Alector, Inc. (NASDAQ: ALEC). It appears to be a financial data point provided by TradingView, a financial markets platform. The content primarily focuses on the company's financial data and gene", "url": "https://www.tradingview.com/symbols/NASDAQ-ALEC/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:53", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Alector, Inc. \u2013 GETTEX:0Z2", "summary": "The article discusses the \"Price to book forward\" metric for Alector, Inc. (GETTEX:0Z2), available on TradingView under its financial data section. It highlights that this specific financial data point is \"Made by humans\" and is part of the comprehensive information available for", "url": "https://www.tradingview.com/symbols/GETTEX-0Z2/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T10:11:45", "published_display": "25 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (NASDAQ: ALEC) director receives new RSU and stock option awards", "summary": "Alector (NASDAQ: ALEC) director Elizabeth A. Garofalo was granted new equity compensation on June 17, 2026. This included 28,700 restricted stock units (RSUs) vesting on June 17, 2027, or the date of the next annual stockholder meeting, and stock options for 9,450 shares vesting ", "url": "https://www.stocktitan.net/sec-filings/ALEC/form-4-alector-inc-insider-trading-activity-cec12f2be4ed.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:39:18", "published_display": "22 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Alector Inc (ALEC) currently has a weak financial status and low operating efficiency, ranking 312 out of 389 in the Biotechnology & Medical Research industry with a financial score of 5.88. The company reported a significant year-over-year decrease in revenue (71.53%) and net pr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/financial-health", "source_name": "TradingKey", "published_at": "2026-06-22T17:09:17", "published_display": "22 Jun 2026 17:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Institutional Confidence", "summary": "Alector Inc (ALEC) has an institutional shareholding score of 7.00, placing it 81st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 80.95%, showing a 17.91% decrease quarter-over-quarter. James Simons is the largest institutional sha", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T03:09:27", "published_display": "19 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Stock Faces Mixed Analyst Target Changes On Tau Therapy Readthrough", "summary": "Alector's fair value remains steady at US$3.10 per share, despite mixed analyst sentiment regarding tau-targeting therapies in Alzheimer's. While some analysts view Biogen's CELIA data as validating the approach and Alector's potential, others caution that the CELIA trial missed ", "url": "https://sg.finance.yahoo.com/news/alector-alec-stock-faces-mixed-001825375.html", "source_name": "Market source", "published_at": "2026-06-19T00:18:00", "published_display": "19 Jun 2026 00:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Alector Inc (ALEC), noting its current valuation score of 6.91 in the Biotechnology & Medical Research industry. It details the stock's current price, market cap, and P/E ratio, while indicating that P/B, P/S, and P/CF data have not y", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:52", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Alector Inc (ALEC), including its current price momentum score, support and resistance levels. It details various technical indicators like MACD, RSI, and moving averages, offering buy, sell, or neutral signals. The analysis suggests ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/technical", "source_name": "TradingKey", "published_at": "2026-06-18T07:39:52", "published_display": "18 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Alector Inc (ALEC), listing major shareholders and providing a breakdown of shareholder types, including investment advisors, hedge funds, and venture capital. It also presents institutional shareholding data over several quarters", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T05:38:57", "published_display": "18 Jun 2026 05:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Inc (ALEC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article concerns Alector Inc (ALEC) and its revenue breakdown by business segments, regional revenue, and profit contribution. However, the article states that relevant data for these categories have not been disclosed by the company yet. It primarily serves as a placeholder", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alec/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T03:38:57", "published_display": "18 Jun 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) director receives 28,700 RSUs and 9,450-share option grant", "summary": "Alector, Inc. director Richard H. Scheller received 28,700 restricted stock units (RSUs) and a stock option for 9,450 shares of common stock, as detailed in a recent Form 4 SEC filing. The RSUs vest on the earlier of June 17, 2027, or the company's next annual stockholder meeting", "url": "https://www.stocktitan.net/sec-filings/ALEC/form-4-alector-inc-insider-trading-activity-d45744dd978d.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:39:52", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (NASDAQ: ALEC) director receives RSU and stock option grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOUlZ0RHBDWFlleEN2V2l5N290ZjhfS24wMGJ3d3RMLWlnakxxaHNPVDJIVWZnTlpFRXR5OXUtUUgtSWZNWUJ2TmdhdS1oUDNrd1JpbDFQNjZ3b3hmWjF1TGhta2pOaE5yRGxncDJQbkpvNHNLc0RweVVMcDBjMjE0Y2R0bWhaRURHZHFlSDkzRU9EUVFfZHNTdVBHTzVIVTBlMl9wTWh3QUY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity grants lift Alector (ALEC) director Errol DeSouza\u2019s holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWG15akVkQnRYYTQ4NGg2eVQ4UC11WWN2dmVaWjhxSWw2Z2RwS21jM3NkNm8wRlROd3JyWEg0V1d1eWhtQl9DZ3hielhnNHQ1WURJZEtiLWVYQzhJVHhVclNPTDJGUVhNYUxzZzBwY2RuajR6RjZEYkVXeFRnYmF6VTJodHdtT1YxRFpmc0lLWTJMdkJGVDhCMVNMdXYxazlram1mcWRIN1Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) director awarded stock and options vesting through 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYmJsdzdsQkhIeHRLWDMxR2hPeWlxcEdBMjhQekxhdXpGQmQxZjN5UzZzZFNtNXNyMUVwTVJJblZKa1BUbERfbHd0d1B4UXplXzlOWngtQzRaVC04TVIzNTg5ajg2cE9FRHhjcDFFMlR3VG9GLWNqSFdsalBiSGdzQVJkbFRudnNzTDlzQjlmV05OeTJyRGdjTzNieEdRUmVTNnZweUV0MjA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Insider Has Just Sold Shares In Alector", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHJtLTJGblZUdFZBSDNrWXNEUXVFZm5WZ1JwRkoyVGVPOGJISU5NUHppZHJ4S2FGRnJ0a3VZcC1CeG13TGVKSzNzUnlOVnMxOXVSb1pQaVJfa2xkSlVCNUs4NHFhc1hLYUFCLW5hZDNhaVpSekNiSUpXcWhHT3I2Uy1DcDBIZHdFZTF0R2tYVC1Gclo5RHAtN1dwZWhvX3BNejBPNGNn?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alector-alec-reports-q1-loss-230508350.html", "source_name": "Zacks", "published_at": "2026-05-07T23:05:08+00:00", "published_display": "07 May 2026 23:05", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/alector-q1-earnings-snapshot-210514149.html", "source_name": "Associated Press", "published_at": "2026-05-07T21:05:14+00:00", "published_display": "07 May 2026 21:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alector-reports-first-quarter-2026-200500095.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T20:05:00+00:00", "published_display": "07 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOaGpUcURHTV9lbTFiY0NMZTJrSC1yQnNpbmt6eld3Q1dJSUUzaDB3YTVMbFJaelduSm5EUHpQa19WX2NQMlN4Z2hQYWp3dTVGeEwtXzJET3BJWm1DN0dBUUR2R2VtdV95UE9OOEt1bDRPaHBUVTBqUzdhYXQwSkpjVUM2SlA4bUdacmN6aUNWS19uUl9UYkZqOFpCWGU?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley raises Alector stock price target on pipeline focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQa3M0NlExSGlHbTlRdFRDWmQxLVc0QVlBVEYwakZWLTRVU3liTnRyZWpzbWNZOEZMRmFKMHZ4RkpwdHYxbkJCaldLNk5McVRqZjBXVUhld2oxTENHcjZEQUtjWVBsaDNGT3JpdFhoWnhQLWNZVTFGd1VQWVNQNVhici1wSWZsNjRPZTFNN3NpYUJaRXctT2c1M0Jpa2tCV3NTRWZQYTdybTVQWXAwbTFLRkJLaHQ4dWJSOGl6OWI5Q2YtTlda?oc=5", "source_name": "Investing.com", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector drops GSK-partnered Alzheimer\u2019s drug (ALEC:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPSjd0TXVrUzQ2Zmx6RXJ0dGI2bXNLSG12bVp5dmZ5bDBYa3Y5MWFpdGhTNlZzYmpNd1RGRUlDRV9Fc0htdVdkLXh0WFcyMDhlcmVCZTRnT0FRLVdQSDlUc2w3TzBvX0NWTjhnRlJ0X2Uxc3VTUmZ3N083b1QycnlSV1hLNTNJd0FY?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNdmt3NGxGdjBsa0IyYkoyaFpGUnRMay12cWMxcHR5cDZZMzFxbzNNcENwTGlQeHBhY1ZfZF9nSXRuMUJXdUJlYW1Hci1hM0JYcnNHcTZPN1JBcVBDeTN6T19UR3IxRnEwcUVTbUpWT1NkN3I1bURYZGQxbFFURGNkc0R2dlFaY29VQjdsbUVDdjc2TV9VekJpd19taWhyakZLbVN0eG1DNlVtak0?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector stock upgraded at Cantor Fitzgerald (ALEC:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPQnlwYjRFOFB5S24zamZ0Zkw5VmN6ZTlUY1FkOGEtWVBMN0dWc2Z2Rk5TMjJtNUR1ZnpTcURWb1c3ZXlkV2JLUDB1cFdqT1d3MklKODhybXd5RlNBMmhRaDdOX01QVzBpTjlrQndQZFJUM3pTcEdjeFMxR0FJMTBtY0tpekc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Stock Jumps On Upgrade, But AL101 Interim Data Will Be Key (NASDAQ:ALEC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQdU9XR0Izdk1pRk5hR2p2cEdvRVl2UFZZWmJIVElsUzBrVTQyMjNOTjdGWGIzNlVkX0tWSjA5REViUjNHaVlDeGN1T2FBVm5CY0tlaTJyNTNGYmN1NDZyTkt1NDdURW5mWlNhZWE1ajN0Mzg3RGxNQjhmdkR1NmtmX0lMSGlvUmpJQkhaMkttaTNhZWpxUVJrOGt6S3UwNkQzM1F1by1RcFF6Zw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-22T08:00:00+00:00", "published_display": "22 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst (ALEC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQNU5jTjlMdEdmaVI3X29vNmVsNElSamR3TmpzdnZONUJZTmZjVEk0a0ZkaFVxSktSTHUyRnFfaHRheG5xZm5uRUlXWU1NQkdlalNldkZsTGNhSmVJazkwOTZnaXlWV3dlUlhhS2R1elhhTVpxcW5kb09tSmdrZ1hmUUh6RTRaR29jTnRFT1laSm1xUWxuSzZuMWxDMUhENlVqUHpadmMzSm52T2g1QWQ4?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Is Down 54.3% After Latozinemab Phase 3 Failure and Major Restructuring \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-24T07:00:00+00:00", "published_display": "24 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Stock Forecast and Price Target 2026 $ALEC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9OT2FUWXB3T09DWllleWRLbk1DbGtiVmk3VjMtSXRlSDdxVHkxOWQxMzhObjE5TmxUSzVBb1hBRk5kdEJVdHRxVkJFS2plNmlSc1pfc2ROdzVIU1pxVlVvWTJRRVgtZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:36:45+00:00", "published_display": "11 May 2024 13:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alector (ALEC) Stock Price, News & Analysis $ALEC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE4wTXZaeWVyMzFoeVJmd3FfNlBEc3NUMHBQMnByS1JBRldxV01pcnVwNE9NU3VNb1dRRDdQZmIyTEh1NmlZVlloaVpWeWx5ZnhGQVdyaV9pQVZOQQ?oc=5", "source_name": "MarketBeat", "published_at": "2019-02-12T01:18:12+00:00", "published_display": "12 Feb 2019 01:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 56, "sentiment_summary": {"positive": 7, "negative": 12, "neutral": 37, "score": 46, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 18.8, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 8.95, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 2.55, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 12}, "market_context": {"has_market_context": true, "latest_close": 1.61, "latest_week": "2026-07-10", "one_week_move": -21.8, "four_week_move": 5.2, "twelve_week_move": -37.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.736432, "market_dynamics_buy_signal": false, "relative_strength": -32.544302, "fair_value_gap": -55.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.8054, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-21.8% over one week, +5.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 7}, {"label": "Seeking Alpha", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "Quartr", "count": 2}, {"label": "MarketBeat", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 3}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "8", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-21.8% over one week, +5.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Alector (ALEC) Proxy filing Summary"}], "updated_at": "2026-07-16T05:41:37.462638+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}